Compare Citius Pharmaceuticals Inc (CTXR) vs Micron Technology, Inc. (MU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Micron Technology, Inc. — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while Micron Technology, Inc. trades at $978.9 (market cap $1.11T). The key difference: Micron Technology, Inc. is far larger — about 75819.7× Citius Pharmaceuticals Inc's market cap, and Micron Technology, Inc. pays a 0.05% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | MU | |
|---|---|---|
Market Cap | $14.64M | $1.11T |
Sector | Health | Technology |
52-Week High | $1.82 | $1.21K |
52-Week Low | $0.53 | $104.88 |
Enterprise Value | $10.86M | $1.09T |
Dividend Yield | — | 0.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Micron Technology (MU) trades at $937.00, down 4.32% today, but maintains strong bullish technical momentum with support near $924. The company demonstrates robust fundamentals, with Q1 2026 EPS beating estimates at $25.11 versus $20.98 expected, and revenue growth accelerating to $37.38 billion in 2025. Analyst sentiment remains overwhelmingly positive, with 81% recommending Buy and a consensus price target of $1,550.
Outlook is favorable driven by AI memory demand and pricing power, though risks include competitive pressure from SK Hynix and cyclical semiconductor volatility. Cash flow trends show strengthening operational performance, with net cash flow turning positive at $2.59 billion in 2025, supporting future growth investments and shareholder returns via dividends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →
